Cordlife Logo

Email

gutmicrobiome@cordlife.com

Customer Service Hotline

+65 6238 0808

Follow Us

Over 60 conditions using GMT as intervention

Currently, there are more than 290 registered clinical trials conducted to establish the role of the gut microbiome in over 60 conditions including allergy, immune system functioning, metabolism, autism and dementia.1,2

Expand All
  • Peanut allergy
  • Human immunodeficiency virus
  • Multiple sclerosis
  • Sjogren's syndrome
  • Rheumatoid arthritis
  • Reactive arthritis
  • Psoriatic arthritis
  • Alopecia areata
  • Clostridioides difficile
  • Helicobacter pylori
  • Spontaneous bacterial peritonitis
  • Urinary tract infection
  • Multidrug-resistant infections
  • Enterobacteriaceae infections
  • Genitourinary system neoplasm
  • Melanoma
  • Non-small cell lung cancer
  • Gastrointestinal cancers
  • Renal cell carcinoma
  • Leukaemia
  • Myeloma
  • Non-Hodgkin lymphoma
  • Hodgkin lymphoma
  • Head and neck squamous cell carcinoma
  • Cutaneous squamous cell carcinoma
  • Colorectal cancer
  • Colitis with diarrhea
  • Ulcerative colitis
  • Crohn's disease
  • Chronic granulomatous disease-associated colitis
  • Irritable bowel syndrome
  • Pouchitis
  • Microscopic colitis
  • Gouty arthritis
  • Ankylosing spondylitis
  • Pulmonary sarcoidosis
  • Sclerosing cholangitis
  • Non-alcoholic fatty liver disease
  • Non-alcoholic steatohepatitis
  • Liver cirrhosis
  • Hepatic encephalopathy
  • Alcoholic hepatitis
  • Chronic liver failure
  • Obesity
  • Type 2 diabetes
  • Metabolic syndrome
  • Type 1 diabetes
  • Parkinson's disease
  • Autism spectrum disorder
  • Major depressive disorder
  • Bipolar depression
  • Epilepsy
  • Pitt-Hopkins syndrome
  • Chronic fatigue syndrome
  • Myalagic encephalomyelitis
  • Dementia
  • Faecal incontinence
  • Graft-versus-host disease (gastrointestinal & steroid resistant)
  • Pancreatitis
  • Caesarean delivery
  • Constipation
  • Psoriasis
  • Hidradenitis suppurativa
  • Coronavirus disease (COVID-19)
  • Cytomegalovirus
  • Hepatitis B

Ongoing research on GMT

GMT has gained acceptance in the medical community and is rapidly being studied for its application on numerous diseases, beyond digestive disorders.

Phase I

Fecal Incontinence

GI System Cancers

H. Pylori infections

HIV

Multiple Sclerosi

Peanut Allergy

Renal Cell Carcinoma

Severe Motility Disorder

Sclerosing Cholangitis

Sjorgen’s Syndrome

Urinary Tract Infection

Approval for Human Trials

Phase II

Acute Pancreatitis

Advanced Melanoma

Alopecia

AML

Ankylosing Spondylitis

Antibiotic Resistance

Autism Spectrum Disorder

Epilepsy

MDD

Metabolic syndrome

Multi-drug Antibiotic Resistance

Obesity

Parkinson’s Disease

Pitt Hopkins Syndrome

Pre-diabetes

Prostate Cancer

Resistant Bacteria

Rheumatoid Arthritis

Type 2 Diabetes

Phase III and beyond

Crohn’s Disease

NAFLD

Ulcerative Colitis

Bacterial Infection

Bipolar Depression

Covid-19

GVHD

IBS

Liver Cirrhosis

Pouchitis

Current and future applications for a healthy microbiome

Treatment for gastrointestinal issues is one of the current and future applications for a healthy microbiome.

Gastrointestinal Issues

Could induce complete clinical remission of C. diff, promising results for IBD and alleviating symptoms of IBS3 (i.e. abdominal discomfort, diarrhea, fatigue)

Cancer treatment is one of the current and future applications for a healthy microbiome.

Cancer Treatment

May promote an immunotherapy response in cancer patients that were previously non-responders.4

Autism treatment is one of the current and future applications for a healthy microbiome.

Autism

May alleviate or reverse symptoms among autistic individuals.5

References

  • 1Park SH, Lee JH, Shin J, et al. Cognitive function improvement after fecal microbiota transplantation in Alzheimer’s dementia patient: a case report. Current Medical and Opinion.2021;1 6. https://www.tandfonline.com/doi/full/10.1080/03007995.2021.1957807. Accessed 16 June 2022.
  • 2 Ongoing and completed FMT clinical trials page. Clinicaltrials.gov website. https://www.clinicaltrials.gov/ct2/results?term=FMT&flds=aby&recrs=b&recrs=a&recrs=f&recrs=d&recrs=e&age_v=&gndr=&type=Intr&rslt=&phase=4&phase=0&phase=1&phase=2&phase=3&phase=5&Search=Apply. Accessed 2 June 2022
  • 3 Tan P, Li X, Shen J, Feng Q. Fecal microbiota transplantation for the treatment of inflammatory bowel disease: An update. Frontiers in Pharmacology. 2020;11. doi:10.3389/fphar.2020.574533 El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2019;69(5):859-867. doi:10.1136/gutjnl-2019-319630 Jessica Allegretti MD. Stool transplants are now standard of care for recurrent C. difficile infections. Harvard Health. https://www.health.harvard.edu/blog/stool-transplants-are-now-standard-of-care-for-recurrent-c-difficile-infections-2019050916576. Published June 3, 2019. Accessed May 28, 2022.
  • 4 Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371(6529):602-609. doi:10.1126/science.abb5920
  • 5 Kang D-W, Adams JB, Coleman DM, et al. Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota. Scientific Reports. 2019;9(1). doi:10.1038/s41598-019-42183-0 Li N, Chen H, Cheng Y, et al. Fecal microbiota transplantation relieves gastrointestinal and autism symptoms by improving the gut microbiota in an open-label study. Frontiers in Cellular and Infection Microbiology. 2021;11. doi:10.3389/fcimb.2021.759435